Alzheimer’s Disease Biomarkers Market (Type of Biomarker: CSF Biomarkers, Genetic Biomarkers, and Blood Biomarkers; and Detection Technique; Molecular Diagnostics and Immunoassays) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2032

The global alzheimer’s disease biomarkers market size was valued at USD 825.2 million in 2022 and is predicted to be worth USD 1.7 billion by 2032, with a CAGR of 7.3% from 2023 to 2032. 

Key Pointers:

• In terms of type of biomarker, the CSF (cerebrospinal fluid) biomarkers segment held major share of the global Alzheimer’s disease biomarkers industry in 2022
• Based on detection technique, the immunoassays segment is likely to account for significant share of the global Alzheimer’s disease biomarkers market growth during the forecast period.
• North America held the largest share of around 36.9% in 2022.
• Asia Pacific is projected to be the fastest growing region during the forecast period.

Alzheimer's disease is a progressive, irreversible neural condition. It is characterized by the degeneration of neurons in the brain that affect memory and other essential central nervous system functions (CNS). Biomarkers are measurable indicators of what is going on in the body. These can be found in blood, other body fluids, organs, and tissues. Some can even be measured digitally. Biomarkers can assist doctors and researchers in tracking health processes, diagnosing diseases & other health conditions, monitoring medication responses, and identifying health risks in individuals.

Alzheimer's disease is a neurodegenerative disorder that causes significant cognitive deficits, behavioral changes, sleep disturbances, and loss of functional autonomy. The number of Alzheimer's patients is rapidly increasing as the world's population ages. The disease is the leading cause of senile dementia and has become a major public health concern. Early diagnosis is important for initiating treatment, which could be more effective at this stage. Hence, scientists' primary focus is on early detection and development of personalized therapeutic solutions for individual patients.

Aging is the most significant risk factor for dementia. As a person gets older, the risk of developing dementia rises significantly. Senile dementia is caused by diseases that result in brain damage such as Alzheimer’s disease or vascular disease. Hence, increase in geriatric population is expected to propel the Alzheimer’s disease biomarkers market demand in the near future.

Alzheimer’s disease biomarkers Market Segmentation

Alzheimer’s disease biomarkers Market Key Players And Regions